Introduction

Celiac disease (CeD) is triggered by gluten peptides that bind to HLA-DQ2 or -DQ8 in the small intestinal lamina propria which leads to gluten specific TH1 T cell activation and expansion, small intestinal inflammation, villous atrophy and intraepithelial lymphocytosis (IEL) (1, 2). With emphasis on the gut-brain axis we analyzed the consequences of active CeD inflammation on immune cell activation in the brain.

Aims & Methods

CeD is associated with symptoms of foggy mind, chronic fatigue and depression (3, 4). The immunological communication between the gut and brain axis has not been studied in-depth in CeD, including the relation of behavior and mental functioning with intestinal immune activation and resultant inflammatory changes in the blood and the brain.
NOD-DQ8 mice were sensitized to gliadin and fed a gluten-containing or gluten-free diet for 2 weeks. Key transcripts in the small intestine and brain were analyzed using qPCR and compared to FACS data of both organs.

Results

The brain is an active site of induced inflammation subsequent to CeD induction of the gut, with a highly significant upregulation of cerebral IL17a, IL23a, IL22b, IL6, IL33, Nlrp3 and COX2. Moreover, the brain dopamine/noradrenaline and neuroactive tryptophane metabolism was upregulated by enhanced production of dopamine beta hydroxylase, kynurenine-3-monooxigenase (KMO) and quinolinate phosphoribosyl transferase (Qprt).

Conclusion

The significant proinflammatory cytokine production in the brain of humanized NOD DQ8 mice with active CeD confirms a gut-brain immune communication in CeD. This is accompanied by elevated transcript levels of inflammation-induced mediators. Importantly, enzymes encoding neurotransmitter synthesis are upregulated, which may explain fatigue and mental dysfunction in patients with active CeD.

References

(1) Lindfors, K., Ciacci, C., Kurppa, K., Lundin, K. E. A., Makharia, G. K., Mearin, M. L., Murray, J. A., Verdu, E. F., & Kaukinen, K. (2019). Coeliac disease. Nature reviews. Disease primers, 5(1), 3. https://doi.org/10.1038/s41572-018-0054-z
(2) Verdu, E. F., & Schuppan, D. (2021). Co-factors, Microbes, and Immunogenetics in Celiac Disease to Guide Novel Approaches for Diagnosis and Treatment. Gastroenterology, 161(5), 1395–1411.e4. https://doi.org/10.1053/j.gastro.2021.08.016
(3) Belpınar, A., Dağ, Y. S., Arıcıoğlu Sülün, A., Yayan, E. H., & Varol, F. İ. (2023). The effect of anxiety and depression levels of children with celiac disease on quality of life. Journal of pediatric nursing, 73, e260–e265. https://doi.org/10.1016/j.pedn.2023.09.019
(4) Sharma, N., Singh, K., & Senapati, S. (2021). Celiac disease poses significant risk in developing depression, anxiety, headache, epilepsy, panic disorder, dysthymia: A meta-analysis. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 40(5), 453–462. https://doi.org/10.1007/s12664-021-01215-2

Introduction

Risankizumab (RZB), a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), demonstrated substantial improvements in clinical and endoscopic outcomes in patients (pts) with active Crohn’s disease (CD) in the phase 3 studies (ADVANCE [NCT03104413], MOTIVATE [NCT03105128], and FORTIFY [NCT03105102]).^1-2 In the FORTIFY study, clinical remission rates at week 52 were higher than expected in responders to induction RZB who were randomized to placebo (WD PBO) for maintenance, suggesting a durable effect of RZB. In this study, we investigated the molecular mechanisms associated with sustained clinical effects of RZB in CD pts in the phase 3 studies.

Aims & Methods

Bulk RNA sequencing was performed on colon biopsies collected longitudinally from a subset of pts in the phase 3 studies (True PBO, n=23; WD PBO, n=29; pooled RZB 180 and 360 mg, n=77) with matched samples at baseline (BL), wk12 (induction), and wk52 (maintenance). Differentially expressed genes (DEGs) from BL to wk52 were identified with linear mixed-effect models (false discovery rate ≤0.05) in all pts as well as in pts who achieved clinical remission (average daily stool frequency ≤2.8 and not worse than BL and average daily abdominal pain score ≤1 and not worse than BL) at wk52 and those who achieved maintenance of clinical remission from wk12 to wk52. Pathway enrichment analyses were performed with Ingenuity Pathway Analysis (IPA). Cell type enrichment analyses based on gut cell signatures from Buckley et al³ was conducted using Gene Set Variation Analysis (GSVA).

Results

Analysis of DEGs in colon biopsies from all pts yielded a highly significant subset of genes modulated from BL to wk52 in the WD PBO and RZB treatment arms. Shared upregulated DEGs across the WD PBO and RZB groups (MT-ND6, MT-ND4, MT-ND5, MT-ATP6, MT-ND4L, MT-ND1, MT-ND2, MT-CYB, MT-ND3, MT-CO2, MT-CO3, MT-CO2 and EIF3C) are associated with reduced mitochondrial dysfunction and upregulation of mitochondrial oxidative phosphorylation. Modulation of these genes were also enriched in pts who achieved wk52 clinical remission as well as pts who achieved maintenance of clinical remission from wk12 to wk52. Next, we validated the enrichment of the MT genes (based on the top 13 upregulated genes) at the patient level and found that all 13 shared MT gene signatures were significantly enriched at wk52 compared to BL and wk12 in both the WD PBO and RZB treatment arms. Additionally, the MT signature scores were comparable between the WD PBO and RZB arms at wk52. Cell type enrichment analyses further revealed that all 13 MT genes were expressed at higher levels in epithelial cells compared to other immune cell subsets, highlighting their potential role in epithelial cell function. These MT genes were also enriched in colonocytes, enterocytes, and LRG+ stem cells of pts who achieved wk52 clinical remission in both WD PBO and RZB groups, with significantly higher expression at wk52 compared to BL and wk12.

Conclusion

In this study, we identified molecular mechanisms indicating an immunometabolic shift, characterized by downregulation of canonical inflammatory pathways (such as neutrophil degranulation) and an enrichment of oxidative phosphorylation and enhanced mitochondrial activity in RZB-treated pts who demonstrated sustained clinical remission through 52 weeks of drug withdrawal. Durable clinical effects observed with RZB could be due to the enrichment of MT genes in colonic epithelial cells in the gut, which may signify RZB’s ability to restore mitochondrial function and energy metabolism.

References

1. Schreiber SW, et al. J Crohn's Colitis. 2021;15(S1).
2. Ferrante M, et al. The Lancet. 2022;399(10340):2031-2046.
3. Thomas T, et al. Nat Immunol. 2024;25:2152–2165.

Disclosure

Author Disclosures
Nick Powell has received research grants from AstraZeneca, Bristol Myers Squibb, CCUK, Celltrion Healthcare, Helmsley Charitable Trust, Pfizer, and Takeda; received personal fees from AbbVie, Allergan, AstraZeneca, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Janssen, Pfizer, Takeda, and Roche; served as a speaker or on the advisory board for AbbVie, Allergan, AstraZeneca, Bristol Myers Squibb, Celgene, Dr Falk, Galapagos, and Vifor; and serves on the data safety monitoring board for AstraZeneca and Bristol Myers Squibb.
Bram Verstockt has received research support from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; speaker’s fees from AbbVie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; consultancy fees from AbbVie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma, and Viatris; and stock options from Vagustim.
Geert D’Haens has received consulting and/or lecture fees from AbbVie, ActoGeniX, AIM, Boehringer Ingelheim, Centocor, ChemoCentryx, Cosmo Technologies, Dr Falk Pharma, Elan Pharmaceuticals, enGene, Ferring, Galapagos, Giuliani SpA, Given Imaging, GlaxoSmithKline, Janssen, MSD, Neovacs, Novo Nordisk, Otsuka, PDL BioPharma, Pfizer, Receptos, Salix, SetPoint, Shire, Schering-Plough, Takeda, Tillotts, UCB Pharma, Versant and Vifor Pharma; research grants from AbbVie, Dr Falk Pharma, Given Imaging, Janssen, MSD and PhotoPill; and speaking honoraria from AbbVie, Ferring, MSD, Norgine, Shire, Tillotts, Tramedico and UCB Pharma.
Naim Al Mahi, Stephen Laroux, Ari Stromberg, Heath Guay, and Buvana Ravishankar are full-time employees of AbbVie and may own AbbVie stock or stock options.
James Lindsay has served as a consultant and an advisory board participant for AbbVie, Atlantic Healthcare, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead, GSK, Janssen, MSD, Napp, Pfizer, Shire, Takeda, and Vifor Pharma; has received speaker fees and sponsorship for academic meetings from AbbVie, Ferring Pharmaceuticals, Janssen, MSD, Napp, Norgine, Pfizer, Shire, Tillotts Pharma, and Takeda; and has received investigator-led research grants from AbbVie, Gilead, Pfizer, Shire and Takeda.


Funding
AbbVie funded this trial and participated in the trial design, research, analysis, data collection, interpretation of data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. AbbVie and the authors thank the patients, study sites, and investigators who participated in this clinical trial.

Introduction

Emerging evidence suggests that poor oral health may play a role in gastrointestinal carcinogenesis through inflammatory and microbiome-mediated mechanisms. However, its association with esophageal cancer remains insufficiently explored.

Aims & Methods

We aimed to assess the association of oral health indicators and oral hygiene behaviors with esophageal cancer risk using both dental health screening and claims-based data. We conducted a population-based case-control study using the Korean National Health Insurance Service (NHIS) database and the National Health Screening (NHS) records. To enhance the reliability of our study, we examined oral hygiene from two complementary perspectives: (1) oral health assessed through dental examinations and questionnaires in the NHS database and (2) periodontal disease status determined based on a claim-based analysis of the NHIS database. Individuals newly diagnosed with esophageal cancer were identified and matched at a 1:4 ratio to cancer-free controls through rigorous propensity score (PS) matching based on sociodemographic factors, comorbidities, lifestyle behaviors, and laboratory parameters. Oral health variables were assessed using national dental screening program data (status of decayed, missing, and filled teeth; gingivitis severity; dental calculus; and self-reported oral hygiene practices) and NHIS claims data identifying periodontal disease using ICD-10 codes and procedure codes. Multivariable-adjusted conditional logistic regression analyses were performed to estimate adjusted odds ratios (aORs) with 95% confidence intervals (CIs).

Results

After PS matching, the oral health analysis included 4,238 cancer cases and 16,904 controls, while the claim-based periodontal disease analysis comprised 18,905 cancer cases and 75,604 matched controls in the final analysis. In multivariable analysis, missing teeth (adjusted OR, 1.16; 95% CI, 1.08–1.25) and inadequate oral hygiene behaviors—including brushing fewer than three times daily (aOR, 1.14; 95% CI, 1.07–1.23), infrequent toothbrushing before bedtime (aOR, 1.08; 95% CI, 1.00–1.16), infrequent use interdental cleaning tools (aOR, 1.10; 95% CI, 1.01–1.19), and dental visits in the past year (aOR, 1.09; 95% CI, 1.02–1.16)—were significantly associated with an increased risk of esophageal cancer. Additionally, claim-based periodontal disease was independently associated with elevated risk (aOR, 1.05; 95% CI, 1.01–1.09). Subgroup analyses revealed consistent associations across smoking and obesity strata, while sex-, age-, and alcohol-stratified analyses demonstrated differential patterns.

Conclusion

This study provides comprehensive, population-based evidence that both clinically assessed dental health indicators and behavioral oral hygiene practices are associated with esophageal cancer risk. The integration of screening-based and claims-based data enhances the validity of the findings and highlights oral health as a potential modifiable risk factor for esophageal cancer prevention.